Guangdong Zhongsheng Pharmaceutical Co., Ltd.

SZSE:002317 Stock Report

Market Cap: CN¥13.1b

Guangdong Zhongsheng Pharmaceutical Future Growth

Future criteria checks 4/6

Guangdong Zhongsheng Pharmaceutical is forecast to grow earnings and revenue by 43.3% and 17.1% per annum respectively while EPS is expected to grow by 42.4% per annum.

Key information

43.3%

Earnings growth rate

42.4%

EPS growth rate

Pharmaceuticals earnings growth18.5%
Revenue growth rate17.1%
Future return on equityn/a
Analyst coverage

Low

Last updated13 Mar 2024

Recent future growth updates

No updates

Recent updates

We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Apr 29
We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Mar 18
Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

Feb 29
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

Earnings and Revenue Growth Forecasts

SZSE:002317 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20253,432443N/AN/A1
12/31/20243,120401N/AN/A1
3/31/20242,505175-36257N/A
12/31/20232,611263-172191N/A
9/30/20232,756353-446-21N/A
6/30/20232,833328-447-37N/A
3/31/20232,747387-466-108N/A
1/1/20232,676322-20563N/A
9/30/20222,597213241441N/A
6/30/20222,545192411617N/A
3/31/20222,489295400598N/A
1/1/20222,429278409623N/A
9/30/20212,409-414-97100N/A
6/30/20212,321-330-15013N/A
3/31/20212,122-423-27126N/A
12/31/20201,896-427-16139N/A
9/30/20201,923251181323N/A
6/30/20202,010207189336N/A
3/31/20202,30724495240N/A
12/31/20192,532318123251N/A
9/30/20192,538454220356N/A
6/30/20192,474464320455N/A
3/31/20192,378439325449N/A
12/31/20182,362436183327N/A
9/30/20182,306455229381N/A
6/30/20182,197447120274N/A
3/31/20182,12543237192N/A
12/31/20171,964420N/A370N/A
9/30/20171,855427N/A223N/A
6/30/20171,837439N/A230N/A
3/31/20171,713432N/A297N/A
12/31/20161,692414N/A338N/A
9/30/20161,673380N/A274N/A
6/30/20161,640371N/A351N/A
3/31/20161,668325N/A334N/A
12/31/20151,578297N/A192N/A
9/30/20151,494276N/A356N/A
6/30/20151,433257N/A219N/A
3/31/20151,367238N/A75N/A
12/31/20141,309225N/A101N/A
9/30/20141,234219N/A96N/A
6/30/20141,190211N/A97N/A
3/31/20141,117194N/A144N/A
12/31/20131,090188N/A111N/A
9/30/20131,048187N/A95N/A
6/30/2013998191N/A118N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002317's forecast earnings growth (43.3% per year) is above the savings rate (2.9%).

Earnings vs Market: 002317's earnings (43.3% per year) are forecast to grow faster than the CN market (24.1% per year).

High Growth Earnings: 002317's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002317's revenue (17.1% per year) is forecast to grow faster than the CN market (14.6% per year).

High Growth Revenue: 002317's revenue (17.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 002317's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.